Abstract: A method for determining the existence of transformed alpha fetal protein in a sample. The first step is mixing said reagents by inversion before use. The second step is providing a microtiter plate with wells coated with synthetic TAFP diluted in a coating buffer, dispensing PSB buffer to wet the well surfaces, waiting a period of time and decanting the microtiter plate. The third step is providing a first washing of the well(s) with a wash buffer for removing unbound material. The fourth step is adding non-fat dry milk to the coating buffer and incubating the microtiter plate for a first period of time at room temperature for blocking nonspecific binding sites. The fifth step is providing a second washing of the well with a wash buffer for removing unbound material. The sixth step is adding anti-TAFP antibody diluted in a binding buffer for a second period of time for allowing the primary antipetide antibodies to bind.

Abstract: The subject invention provides non-naturally occurring peptides capable of inhibiting growth factor-stimulated growth of cells. The peptide can be utilized to inhibit growth factor-stimulated growth, such growth factors including, for example, gonadotropins, peptide hormones, synthetic growth factors, and ligands, the ligand having a receptor that is a member of the steroid/thyroid hormone/vitamin receptor superfamily. Also provided are DNA sequences encoding the peptides and methods of producing and using the peptides.

Abstract: The subject invention provides non-naturally occurring peptides capable of inhibiting growth factor-stimulated growth of cells. The peptide can be utilized to inhibit growth factor-stimulated growth, such growth factors including, for example, gonadotropins, peptide hormones, synthetic growth factors, and ligands, the ligand having a receptor that is a member of the steroid/thyroid hormone/vitamin receptor superfamily. Also provided are DNA sequences encoding the peptides and methods of producing and using the peptides.